We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comment on "Sodium glucose cotransporter 2 inhibitors and gout risk".
- Authors
Lai, Shih-Wei; Hwang, Bing-Fang; Liu, Chiu‑Shong; Liao, Kuan-Fu
- Abstract
A letter to the editor of Clinical Rheumatology discusses a study that found a lower risk of gout among patients with type 2 diabetes mellitus (T2DM) who used sodium-glucose cotransporter 2 inhibitors (SGLT2-I). The letter highlights a new theory that SGLT2-I may have a urate-lowering effect, potentially reducing the risk of gout. The authors also discuss the use of prescription symmetry sequence analysis as a valuable tool in pharmacoepidemiology to explore the association between SGLT2-I use and the risk of gout. The letter concludes by expressing appreciation for the research conducted by Dr. Wood et al. and its contribution to the field.
- Subjects
URATES; GLUCOSE transporters; GOUT; SODIUM-glucose cotransporter 2 inhibitors
- Publication
Clinical Rheumatology, 2024, Vol 43, Issue 2, p835
- ISSN
0770-3198
- Publication type
Article
- DOI
10.1007/s10067-023-06791-6